4 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 4 | Unknown 2, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Biomed Industries, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome Bionetide, Placebo - Rett Syndrome | Phase 3 | Recruiting | Biomed Industries, Inc. | 210 | 2026-09-30 | 2026-03-27 |
| Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide - Obesity and Overweight | Phase 2 | Not yet recruiting | Biomed Industries, Inc. | 224 | 2026-08-15 | 2026-03-27 |
| Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition Drug: Placebo daily and orally, NA-931, dose 1, daily and orally, NA-931, dose2, daily and orally - Weight Loss, Obesity | Phase 2 | Completed | Biomed Industries, Inc. | 126 | 2024-07-19 | 2025-05-23 |
| Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus NA-931, Placebo - Overweight or Obesity, Type 2 Diabetes | Phase 1 | Completed | Biomed Industries, Inc. | 74 | 2024-05-06 | 2024-09-27 |
| To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome Drug: Bionetide, Placebo - Rett Syndrome | Phase 2 / Phase 3 | Completed | Biomed Industries, Inc. | 187 | 2024-03-15 | 2025-02-27 |
| NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone - Coronavirus Infection, Severe Acute Respiratory Infection | Phase 2 / Phase 3 | Unknown | Biomed Industries, Inc. | 525 | 2022-06-15 | 2022-02-16 |
| A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 Biological: oral polio vaccine, Comparable Placebo, NA-831 - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Unknown | Biomed Industries, Inc. | 3600 | 2020-11-01 | 2020-09-09 |
| Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg - Covid19, Corona Virus Infection | Phase 1 | Unknown | Biomed Industries, Inc. | 45 | 2020-09-15 | 2020-07-21 |
| A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Completed | Biomed Industries, Inc. | 126 | 2018-09-15 | 2020-06-30 |
COVID-19 (3) · Obesity (3) · Overweight (3) · Severe Acute Respiratory Syndrome (3) · Cognitive Dysfunction (2) · Coronavirus Infections (2) · Genetic Diseases, X-Linked (2) · Rett Syndrome (2) · Alzheimer Disease (1) · Body Weight (1) · Body Weight Changes (1) · Dementia, Vascular (1) · Diabetes Mellitus, Type 2 (1) · Lewy Body Disease (1) · Nerve Degeneration (1)
Atazanavir Sulfate (1) · Dexamethasone (1) · Drug Combinations (1) · Poliovirus Vaccine, Oral (1) · Tirzepatide (1) · remdesivir (1)
United States (6) · Australia (5) · New Zealand (3)
Lloyd Tran, PhD (7) · David Nguyen, PhD (2) · Lloyd L Tran, PhD (1) · Lloyd L. Tran, PhD (1) · Zung V Tran, PhD (1)